Home / Deep Research / Budd-Chiari Syndrome

Budd-Chiari Syndrome

Budd–Chiari Syndrome (BCS) — Disease Characteristics Research Report

2026-05-06
Falcon MONDO:0010947 Model: Edison Scientific Literature 53 citations

Budd–Chiari Syndrome (BCS) — Disease Characteristics Research Report

Executive summary

Budd–Chiari syndrome (BCS) is hepatic venous outflow tract obstruction (HVOTO) causing hepatic congestion, portal hypertension, and progressive fibrosis/cirrhosis, defined in the absence of right heart failure or constrictive pericarditis. It is rare (typically ~0.35–0.8 cases per million per year in Europe) but clinically high impact; most patients have an underlying prothrombotic condition—especially myeloproliferative neoplasms (MPN) with JAK2 V617F—and contemporary management relies on anticoagulation plus endovascular restoration/decompression (angioplasty/stent or TIPS), with transplantation reserved for refractory/advanced disease. (valla2018budd–chiarisyndromehepaticvenous pages 1-2, ollivierhourmand2018theepidemiologyof pages 1-2)

1. Disease information

1.1 Definition and overview (current understanding)

  • Definition: BCS is partial or complete impairment/obstruction of hepatic venous drainage/outflow (from small hepatic venules to the IVC/right atrium), excluding obstruction due to right-sided heart failure or constrictive pericarditis. (porrello2023buddchiarisyndromeimaging pages 1-2, valla2018budd–chiarisyndromehepaticvenous pages 1-2)
  • Synonyms / alternative names:
  • Hepatic venous outflow tract obstruction (HVOTO) (valla2018budd–chiarisyndromehepaticvenous pages 1-2)
  • Hepatic vein thrombosis (commonly used clinically; BCS is a form of hepatic venous thrombosis) (valla2018budd–chiarisyndromehepaticvenous pages 1-2)
  • Classification (etiologic):
  • Primary BCS: obstruction from thrombosis (or evolution to fibrotic stenosis) within hepatic veins/IVC. (porrello2023buddchiarisyndromeimaging pages 1-2, valla2018budd–chiarisyndromehepaticvenous pages 1-2)
  • Secondary BCS: obstruction from external compression or tumor invasion/encasement. (porrello2023buddchiarisyndromeimaging pages 1-2, valla2018budd–chiarisyndromehepaticvenous pages 1-2)

1.2 Key identifiers/codes (from retrieved sources)

  • ICD-10: I82.0 used for BCS case ascertainment in French national hospital discharge data. (ollivierhourmand2018theepidemiologyof pages 2-3)
  • MeSH / OMIM / Orphanet / MONDO: Not directly extractable from the retrieved texts in this run; therefore not reported here.

1.3 Evidence source type

Most information in this report comes from aggregated disease-level resources (systematic reviews, national cohorts, guidelines) plus selected case reports for rarer etiologies and prevention messaging. (porrello2023buddchiarisyndromeimaging pages 1-2, ollivierhourmand2018theepidemiologyof pages 1-2, joueidi2024transjugularintrahepaticportosystemic pages 1-2)

2. Etiology

2.1 Disease causal factors (mechanistic categories)

2.2 Risk factors (with quantitative data where available)

2.2.1 MPN and somatic mutations (JAK2/CALR/MPL)

2.2.2 Inherited thrombophilias and APS/PNH/Behçet

2.2.3 Hormonal and reproductive factors

  • France cohort (women of child-bearing age): recent oral contraceptive use 36 (35.0%). (ollivierhourmand2018theepidemiologyof pages 5-5)
  • Valla 2009 (primary BCS expert review): explicitly recommends stopping oral contraceptives and other hormonal therapy as part of management/risk reduction. (valla2009primarybuddchiarisyndrome. pages 6-7)

2.2.4 Local inflammatory/mechanical factors and secondary causes

  • France discharge database: among primary BCS incident cases, local factors were prominent in coding (e.g., 38.3% local factors among those with risk-factor ICD-10 codes), highlighting potential differences between referral-cohort phenotyping and administrative coding. (ollivierhourmand2018theepidemiologyof pages 5-5)
  • Secondary BCS example: extraluminal compression from a hydatid cyst is described as a rare but fatal cause in an endemic-area case report. (ollivierhourmand2018theepidemiologyof pages 3-5)

2.3 Protective factors

No specific genetic protective variants were identified in the retrieved texts. Protective/mitigating factors are mainly treatment-based (anticoagulation, cytoreduction, restoration of outflow). (magaz2020buddchiarisyndromeanticoagulation pages 1-2, martens2015buddchiarisyndrome pages 5-7)

2.4 Gene–environment interactions

BCS frequently reflects interaction of inherited/acquired thrombophilia with environmental/hormonal exposures, exemplified by oral contraceptives in patients with clonal MPN thrombophilia (JAK2 V617F) or combined thrombophilic defects. (karns2024a27yearoldfemale pages 1-2, valla2009primarybuddchiarisyndrome. pages 6-7)

3. Phenotypes

3.1 Clinical phenotypes and frequencies

BCS can be acute, subacute/chronic, asymptomatic, or fulminant. (porrello2023buddchiarisyndromeimaging pages 1-2)

Common presenting features (France 2010 cohort): - Ascites 122/164 (74.4%) - Hepatomegaly 115/164 (70.1%) - Abdominal pain 113/156 (72.4%) - Esophageal varices 74/135 (54.8%) - Splenomegaly 78/159 (49.1%) - Jaundice 27/133 (20.3%) (ollivierhourmand2018theepidemiologyof pages 2-3)

From imaging review (Porrello 2023): ascites 62–85%, hepatomegaly ~67%, pain ~61%, varices ~58%, GI bleeding 5–21%; concomitant portal vein thrombosis ~10–15% (worse prognosis). (porrello2023buddchiarisyndromeimaging pages 2-3)

3.2 Laboratory abnormalities

BCS can present with normal liver tests, but AST/ALT can rise markedly in acute/fulminant disease; ascites often has a portal-hypertension pattern (e.g., SAAG ≥1.1 g/dL noted as supportive in one review). (goel2015budd–chiarisyndromeinvestigation pages 1-2)

3.3 Complications and quality-of-life impact

3.4 Suggested HPO terms (examples)

4. Genetic / molecular information

4.1 Causal genes (risk/etiology genes rather than single-gene “causal disease”)

BCS is not classically monogenic; it is a complex thrombotic phenotype with strong association to clonal hematopoiesis and thrombophilia genes.

Key genes/molecular drivers in relevant etiologies: - JAK2 (somatic V617F mutation) in MPN-associated BCS (ollivierhourmand2018theepidemiologyof pages 3-5, valla2018budd–chiarisyndromehepaticvenous pages 2-4) - CALR (somatic frameshift mutations) uncommon but present in a minority of JAK2-negative MPN-SVT (plompen2015somaticcalreticulinmutations pages 1-2) - MPL (MPN driver; mentioned as relevant in BCS work-up) (valla2018budd–chiarisyndromehepaticvenous pages 2-4)

4.2 Pathogenic variants / prothrombotic variants

  • Factor V Leiden (F5): 12–31% reported in European cohorts; table summary ~20%. (valla2018budd–chiarisyndromehepaticvenous pages 2-4)
  • Prothrombin G20210A (F2): table ~7% Europe vs 0% China. (valla2018budd–chiarisyndromehepaticvenous pages 2-4)
  • Antiphospholipid syndrome: ~15% in Europe (table). (valla2018budd–chiarisyndromehepaticvenous pages 2-4)

Variant-level nomenclature and allele frequencies in population databases (gnomAD) were not available in retrieved sources.

4.3 Somatic vs germline

  • MPN drivers (JAK2, CALR, MPL) are somatic in the hematopoietic compartment; inherited thrombophilias (F5 Leiden, F2 G20210A) are germline. (plompen2015somaticcalreticulinmutations pages 1-2, valla2018budd–chiarisyndromehepaticvenous pages 2-4)

5. Environmental information

Environmental/lifestyle triggers are primarily hormonal exposure (estrogen-containing oral contraceptives) and pregnancy/puerperium as prothrombotic states. (ollivierhourmand2018theepidemiologyof pages 5-5, valla2009primarybuddchiarisyndrome. pages 6-7)

Infectious agents are not typical primary causes, but secondary BCS can arise from space-occupying lesions (e.g., hydatid cyst) in endemic areas. (ollivierhourmand2018theepidemiologyof pages 3-5)

6. Mechanism / pathophysiology

6.1 Causal chain

1) Trigger: systemic thrombophilia (e.g., MPN/JAK2, APS, inherited thrombophilia) or secondary compression/invasion. (valla2018budd–chiarisyndromehepaticvenous pages 2-4, porrello2023buddchiarisyndromeimaging pages 1-2) 2) Vascular event: hepatic vein/IVC obstruction and thrombosis. (valla2018budd–chiarisyndromehepaticvenous pages 1-2) 3) Hemodynamic consequence: sinusoidal congestion and increased sinusoidal pressure → portal hypertension and collateral formation. (porrello2023buddchiarisyndromeimaging pages 1-2, rossle2024fibrosisprogressionina pages 1-2) 4) Tissue injury: congestion-related hepatocyte hypoxia/necrosis; evolving fibrosis/cirrhosis; regenerative nodules. (rossle2024fibrosisprogressionina pages 1-2, porrello2023buddchiarisyndromeimaging pages 3-5) 5) Clinical manifestations: ascites, hepatomegaly, pain, varices/bleeding; in severe cases acute liver failure. (ollivierhourmand2018theepidemiologyof pages 2-3, craciun2024tipswitha pages 1-2)

6.2 Molecular/cellular processes (suggested GO / CL)

  • GO biological processes (suggested):
  • blood coagulation (GO:0007596)
  • platelet activation (GO:0030168)
  • inflammatory response (GO:0006954)
  • response to hypoxia (GO:0001666)
  • extracellular matrix organization / fibrosis (GO:0030198)
  • Cell types (CL suggestions):
  • vascular endothelial cell (CL:0000115)
  • hepatocyte (CL:0000182)
  • hepatic stellate cell (CL:0000632)
  • megakaryocyte (CL:0000554) / myeloid lineage cells relevant to MPN (valla2018budd–chiarisyndromehepaticvenous pages 2-4)

6.3 Epigenetics / multi-omics

No BCS-specific epigenomic or multi-omic signatures were available in the retrieved evidence set.

7. Anatomical structures affected

Suggested UBERON terms (examples): - Liver — UBERON:0002107 - Hepatic vein — UBERON:0001638 - Inferior vena cava — UBERON:0001072 - Portal vein — UBERON:0001616

8. Temporal development

9. Inheritance and population

9.1 Epidemiology (quantitative)

9.2 Demographics

9.3 Inheritance patterns

BCS itself is not inherited as a Mendelian disorder; predisposition can arise from germline thrombophilia variants and acquired somatic MPN mutations. (valla2018budd–chiarisyndromehepaticvenous pages 2-4, plompen2015somaticcalreticulinmutations pages 1-2)

10. Diagnostics

10.1 Diagnostic principle

Diagnosis requires radiologic demonstration of hepatic venous outflow obstruction (noninvasive first-line), with biopsy reserved for uncertain/small-vessel disease. (porrello2023buddchiarisyndromeimaging pages 3-5, porrello2023buddchiarisyndromeimaging pages 2-3)

10.2 Imaging tests and performance

10.3 Key imaging signs (with frequencies)

From Porrello 2023 (frequencies across studies): - Splenomegaly 78% - Inhomogeneous parenchyma 76% - Intrahepatic collaterals 73% - Caudate hypertrophy 67% - Ascites 56% - Extrahepatic collaterals 44% (porrello2023buddchiarisyndromeimaging pages 3-5)

Specificity note: a direct US sign plus caudate lobe hypertrophy reported as 100% specificity for BCS. (porrello2023buddchiarisyndromeimaging pages 3-5)

10.4 Biopsy / histopathology

10.5 Differential diagnosis

BCS needs differentiation from sinusoidal obstruction syndrome and cardiac/pericardial causes of hepatic congestion. (porrello2023buddchiarisyndromeimaging pages 1-2, ollivierhourmand2018theepidemiologyof pages 2-3)

11. Outcome / prognosis

11.1 Untreated natural history

Natural history is poor; multiple sources emphasize high mortality without treatment (e.g., case series and reviews cite very low long-term survival), but exact untreated survival statistics were not extractable from the retrieved evidence excerpts in this run. One 2024 cohort paper reiterates that untreated BCS has very poor prognosis and cites historical estimates (50% mortality at 2 years; <10% survival at 3 years) within its discussion. (joueidi2024transjugularintrahepaticportosystemic pages 1-2)

11.2 Survival with modern therapy

11.3 Prognostic scores (examples of performance)

From a 2022 review summarizing published cutoffs: - Rotterdam 5-year survival: Class I 89%, Class II 74%, Class III 42%. (gavriilidis2022stateofthe pages 3-5) - BCS-TIPSS 1-year OLT-free survival: score <7: 95% vs >7: 12%. (gavriilidis2022stateofthe pages 3-5)

12. Treatment

12.1 Core strategy (stepwise algorithm)

A widely endorsed approach: anticoagulation and management of underlying thrombophilia → endovascular recanalization (angioplasty ± stent) for short lesions → TIPS for decompression if needed → liver transplantation for refractory/advanced disease. (rossle2023interventionaltreatmentof pages 1-2, mukhiya2023survivalandclinical pages 1-2)

Visual evidence (treatment algorithm): (rossle2023interventionaltreatmentof media 5657bdfb)

12.2 Pharmacotherapy

12.3 Endovascular and interventional procedures (real-world outcomes)

  • Angioplasty ± stent (short webs/stenoses): technical success >90%; routine primary stenting reduces restenosis (2% with stent vs 40% without; 3-yr restenosis-free survival 96% vs 60.4%). (rossle2023interventionaltreatmentof pages 1-2)
  • TIPS: successful in ~95% of patients in experienced hands; PTFE-covered stents improved long-term patency; reported 5- and 10-year survival ~90% and 80% in an interventional review. (rossle2023interventionaltreatmentof pages 1-2)

12.4 Liver transplantation

Reserved for patients who fail/are not candidates for durable endovascular therapy, or with progressive failure/HCC. Post-transplant recurrence of hepatic vein thrombosis can approach ~20% without adequate long-term anticoagulation. (magaz2020buddchiarisyndromeanticoagulation pages 4-5)

12.5 Suggested MAXO terms (examples)

(These MAXO IDs are suggested mappings; not provided in the retrieved texts.)

13. Prevention

13.1 Primary prevention (risk-factor modification)

  • Avoid estrogen-containing oral contraceptives/hormonal therapy in at-risk patients; Valla 2009 explicitly recommends stopping oral contraceptives and hormonal therapy in primary BCS management, and a 2024 case report highlights combined OCPs as contraindicated in JAK2-mutated MPN patients due to thrombosis risk. (valla2009primarybuddchiarisyndrome. pages 6-7, karns2024a27yearoldfemale pages 1-2)
  • MPN thrombosis prevention: cytoreduction and disease control; one review notes in PV targeting hematocrit <45% reduces major thrombosis risk (evidence imported from PV trials). (magaz2020buddchiarisyndromeanticoagulation pages 1-2)

13.2 Secondary prevention (prevent recurrence/extension)

13.3 Tertiary prevention (prevent complications)

Protective factors beyond these clinical interventions were not identified.

14. Other species / natural disease

Naturally occurring BCS-like hepatic venous outflow obstruction is reported in veterinary contexts: - Dogs: endovascular stent use in three dogs with Budd–Chiari syndrome is reported in the veterinary literature. ()

15. Model organisms

Experimental models exist to study hepatic venous outflow obstruction and mechanisms: - Rat model: BCS model via partial ligation of the IVC with biochemical measures of hypoxia/oxidative stress changes over time. () - Canine model: diffuse hepatic vein obstruction via endovascular occlusion to mimic human BCS. ()

Recent developments (2023–2024 prioritized)

1) Imaging synthesis and meta-analytic performance estimates: Porrello 2023 provides pooled sensitivity/specificity estimates and sign frequencies and highlights the centrality of radiology for diagnosis and surveillance. (Published 2023-07; https://doi.org/10.3390/diagnostics13132256) (porrello2023buddchiarisyndromeimaging pages 3-5, porrello2023buddchiarisyndromeimaging pages 5-8) 2) Interventional outcomes and debate on early intervention: Rössle 2023 argues the conventional step-up algorithm may be “unproven” and supports earlier angioplasty/TIPS, backed by high technical success and survival estimates and the impact of covered stents on patency. (Published 2023-04; https://doi.org/10.3390/diagnostics13081458) (rossle2023interventionaltreatmentof pages 1-2, rossle2023interventionaltreatmentof pages 13-14) 3) Real-world covered-stent TIPS outcomes: A 2024 single-center cohort reports very high 5-year survival (~97.7%) after covered-stent TIPS. (Published 2024-10; https://doi.org/10.3390/jcm13195858) (joueidi2024transjugularintrahepaticportosystemic pages 1-2) 4) Long-term fibrosis tracking after TIPS: 2024 transient elastography follow-up suggests fibrosis is often advanced and may develop early; timing of TIPS did not change stiffness trajectories in that cohort. (Published 2024-02; https://doi.org/10.3390/diagnostics14030344) (rossle2024fibrosisprogressionina pages 1-2)

Current applications and real-world implementation

BCS care is typically concentrated in referral centers that can deliver: (i) rapid imaging confirmation, (ii) multidisciplinary thrombophilia/MPN work-up, (iii) anticoagulation with variceal prophylaxis, and (iv) endovascular expertise for recanalization and TIPS, with transplant backup. (porrello2023buddchiarisyndromeimaging pages 3-5, magaz2020buddchiarisyndromeanticoagulation pages 4-5)

Clinical trials and registries (ClinicalTrials.gov)

  • NCT06960473 (2025; not yet recruiting): randomized trial IVUS-guided vs DSA-guided intervention; n=260; primary endpoint restenosis at 1–12 months. (NCT06960473 chunk 1)
  • NCT02201485 (2014; completed): randomized PTA alone vs PTA+stent; n=88; primary endpoint reocclusion over 2 years; secondary endpoints survival/complications/symptom recurrence. (NCT02201485 chunk 1)
  • NCT05117684 (2021; completed): retrospective comparison of balloon-occluded thrombolysis vs conventional catheter thrombolysis for occluded DIPSS stents; n=33; endpoints include re-stenting, thrombolytic dose, patency at 1 month. (NCT05117684 chunk 1)
  • NCT05123326 (2021; recruiting): prospective global coagulation assessment in PVT and BCS/HVOTO including genetic testing (JAK2, CALR, FVL) and outcomes up to 3 years. (NCT05123326 chunk 2)
  • NCT03541057 (VALID registry; Vienna): prospective observational cohort/biobank including BCS; target ~200; primary endpoint time to first hepatic decompensation. (NCT03541057 chunk 1)

Limitations and gaps

  • Ontology identifiers (MONDO, Orphanet, MeSH IDs) were not captured in the retrieved sources, so this report cannot provide verified values.
  • Several key “landmark” outcome papers (e.g., Murad et al. Ann Intern Med 2009) were retrieved but not fully mined here for untreated vs treated survival due to time constraints; however, multiple independent sources in this evidence set provide quantitative modern survival and prognostic score performance. (gavriilidis2022stateofthe pages 3-5, rossle2023interventionaltreatmentof pages 1-2)

URLs and publication dates (selected key sources)

References

  1. (valla2018budd–chiarisyndromehepaticvenous pages 1-2): Dominique-Charles Valla. Budd–chiari syndrome/hepatic venous outflow tract obstruction. Hepatology International, 12:168-180, Feb 2018. URL: https://doi.org/10.1007/s12072-017-9810-5, doi:10.1007/s12072-017-9810-5. This article has 172 citations and is from a peer-reviewed journal.

  2. (ollivierhourmand2018theepidemiologyof pages 1-2): Isabelle Ollivier-Hourmand, Manon Allaire, Nathalie Goutte, Rémy Morello, Carine Chagneau-Derrode, Odile Goria, Jerôme Dumortier, Jean Paul Cervoni, Sébastien Dharancy, Nathalie Ganne-Carrié, Christophe Bureau, Nicolas Carbonell, Armand Abergel, Jean Baptiste Nousbaum, Rodolphe Anty, Hélène Barraud, Marie Pierre Ripault, Victor De Ledinghen, Anne Minello, Frédéric Oberti, Sylvie Radenne, Noelle Bendersky, Olivier Farges, Isabelle Archambeaud, Anne Guillygomarc’h, Marie Ecochard, Violaine Ozenne, Marie Noelle Hilleret, Eric Nguyen-Khac, Barbara Dauvois, Jean Marc Perarnau, Pascale Lefilliatre, Jean Jacques Raabe, Michel Doffoel, Jean Philippe Becquart, Eric Saillard, Dominique Valla, Thong Dao, and Aurélie Plessier. The epidemiology of budd-chiari syndrome in france. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 50 9:931-937, Sep 2018. URL: https://doi.org/10.1016/j.dld.2018.04.004, doi:10.1016/j.dld.2018.04.004. This article has 63 citations.

  3. (porrello2023buddchiarisyndromeimaging pages 1-2): Giorgia Porrello, Giuseppe Mamone, and Roberto Miraglia. Budd-chiari syndrome imaging diagnosis: state of the art and future perspectives. Diagnostics, 13:2256, Jul 2023. URL: https://doi.org/10.3390/diagnostics13132256, doi:10.3390/diagnostics13132256. This article has 35 citations.

  4. (ollivierhourmand2018theepidemiologyof pages 2-3): Isabelle Ollivier-Hourmand, Manon Allaire, Nathalie Goutte, Rémy Morello, Carine Chagneau-Derrode, Odile Goria, Jerôme Dumortier, Jean Paul Cervoni, Sébastien Dharancy, Nathalie Ganne-Carrié, Christophe Bureau, Nicolas Carbonell, Armand Abergel, Jean Baptiste Nousbaum, Rodolphe Anty, Hélène Barraud, Marie Pierre Ripault, Victor De Ledinghen, Anne Minello, Frédéric Oberti, Sylvie Radenne, Noelle Bendersky, Olivier Farges, Isabelle Archambeaud, Anne Guillygomarc’h, Marie Ecochard, Violaine Ozenne, Marie Noelle Hilleret, Eric Nguyen-Khac, Barbara Dauvois, Jean Marc Perarnau, Pascale Lefilliatre, Jean Jacques Raabe, Michel Doffoel, Jean Philippe Becquart, Eric Saillard, Dominique Valla, Thong Dao, and Aurélie Plessier. The epidemiology of budd-chiari syndrome in france. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 50 9:931-937, Sep 2018. URL: https://doi.org/10.1016/j.dld.2018.04.004, doi:10.1016/j.dld.2018.04.004. This article has 63 citations.

  5. (joueidi2024transjugularintrahepaticportosystemic pages 1-2): Faisal Joueidi, Amnah Alhanaee, Hamad Alsuhaibani, Ali Albenmousa, Ahmad Joueidi, Ahmed Elhassan, Abdallah Nabeel Nasir, Kris Ann Hervera Marquez, Saad Alghamdi, Waleed Al Hamoudi, Saad Abualganam, Dieter Broering, and Khalid Ibrahim Bzeizi. Transjugular intrahepatic portosystemic shunt for budd–chiari syndrome: a single-centre experience. Journal of Clinical Medicine, 13:5858, Oct 2024. URL: https://doi.org/10.3390/jcm13195858, doi:10.3390/jcm13195858. This article has 0 citations.

  6. (rossle2024fibrosisprogressionina pages 1-2): Martin Rössle, Dominik Bettinger, Lukas Sturm, Marlene Reincke, Robert Thimme, and Michael Schultheiss. Fibrosis progression in patients with budd–chiari syndrome and transjugular intrahepatic portosystemic shunt (tips): a long-term study using transient elastography. Diagnostics, 14:344, Feb 2024. URL: https://doi.org/10.3390/diagnostics14030344, doi:10.3390/diagnostics14030344. This article has 3 citations.

  7. (valla2018budd–chiarisyndromehepaticvenous pages 2-4): Dominique-Charles Valla. Budd–chiari syndrome/hepatic venous outflow tract obstruction. Hepatology International, 12:168-180, Feb 2018. URL: https://doi.org/10.1007/s12072-017-9810-5, doi:10.1007/s12072-017-9810-5. This article has 172 citations and is from a peer-reviewed journal.

  8. (ollivierhourmand2018theepidemiologyof pages 3-5): Isabelle Ollivier-Hourmand, Manon Allaire, Nathalie Goutte, Rémy Morello, Carine Chagneau-Derrode, Odile Goria, Jerôme Dumortier, Jean Paul Cervoni, Sébastien Dharancy, Nathalie Ganne-Carrié, Christophe Bureau, Nicolas Carbonell, Armand Abergel, Jean Baptiste Nousbaum, Rodolphe Anty, Hélène Barraud, Marie Pierre Ripault, Victor De Ledinghen, Anne Minello, Frédéric Oberti, Sylvie Radenne, Noelle Bendersky, Olivier Farges, Isabelle Archambeaud, Anne Guillygomarc’h, Marie Ecochard, Violaine Ozenne, Marie Noelle Hilleret, Eric Nguyen-Khac, Barbara Dauvois, Jean Marc Perarnau, Pascale Lefilliatre, Jean Jacques Raabe, Michel Doffoel, Jean Philippe Becquart, Eric Saillard, Dominique Valla, Thong Dao, and Aurélie Plessier. The epidemiology of budd-chiari syndrome in france. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 50 9:931-937, Sep 2018. URL: https://doi.org/10.1016/j.dld.2018.04.004, doi:10.1016/j.dld.2018.04.004. This article has 63 citations.

  9. (plompen2015somaticcalreticulinmutations pages 1-2): E. P. C. Plompen, P. J. M. Valk, I. Chu, S. D. Murad, A. Plessier, F. Turon, J. Trebicka, M. Primignani, J. C. Garcia-Pagan, D. C. Valla, H. L. A. Janssen, and F. W. G. Leebeek. Somatic calreticulin mutations in patients with budd-chiari syndrome and portal vein thrombosis. Haematologica, 100:e226-e228, Feb 2015. URL: https://doi.org/10.3324/haematol.2014.120857, doi:10.3324/haematol.2014.120857. This article has 60 citations.

  10. (morsia2024exploringthemolecular pages 1-2): Erika Morsia, Elena Torre, Francesco Martini, Sonia Morè, Antonella Poloni, Attilio Olivieri, and Serena Rupoli. Exploring the molecular aspects of myeloproliferative neoplasms associated with unusual site vein thrombosis: review of the literature and latest insights. International Journal of Molecular Sciences, 25:1524, Jan 2024. URL: https://doi.org/10.3390/ijms25031524, doi:10.3390/ijms25031524. This article has 9 citations.

  11. (ollivierhourmand2018theepidemiologyof pages 5-6): Isabelle Ollivier-Hourmand, Manon Allaire, Nathalie Goutte, Rémy Morello, Carine Chagneau-Derrode, Odile Goria, Jerôme Dumortier, Jean Paul Cervoni, Sébastien Dharancy, Nathalie Ganne-Carrié, Christophe Bureau, Nicolas Carbonell, Armand Abergel, Jean Baptiste Nousbaum, Rodolphe Anty, Hélène Barraud, Marie Pierre Ripault, Victor De Ledinghen, Anne Minello, Frédéric Oberti, Sylvie Radenne, Noelle Bendersky, Olivier Farges, Isabelle Archambeaud, Anne Guillygomarc’h, Marie Ecochard, Violaine Ozenne, Marie Noelle Hilleret, Eric Nguyen-Khac, Barbara Dauvois, Jean Marc Perarnau, Pascale Lefilliatre, Jean Jacques Raabe, Michel Doffoel, Jean Philippe Becquart, Eric Saillard, Dominique Valla, Thong Dao, and Aurélie Plessier. The epidemiology of budd-chiari syndrome in france. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 50 9:931-937, Sep 2018. URL: https://doi.org/10.1016/j.dld.2018.04.004, doi:10.1016/j.dld.2018.04.004. This article has 63 citations.

  12. (fan2020prevalenceofprothrombotic pages 1-2): Jiahao Fan, Qiuhe Wang, Bohan Luo, Hui Chen, Zhengyu Wang, Jing Niu, Jie Yuan, Xulong Yuan, Wei Bai, Chuangye He, Wengang Guo, Kai Li, Zhanxin Yin, Daiming Fan, and Guohong Han. Prevalence of prothrombotic factors in patients with budd–chiari syndrome or non‐cirrhotic nonmalignant portal vein thrombosis: a hospital‐based observational study. Journal of Gastroenterology and Hepatology, 35:1215-1222, Dec 2020. URL: https://doi.org/10.1111/jgh.14925, doi:10.1111/jgh.14925. This article has 28 citations and is from a peer-reviewed journal.

  13. (ollivierhourmand2018theepidemiologyof pages 5-5): Isabelle Ollivier-Hourmand, Manon Allaire, Nathalie Goutte, Rémy Morello, Carine Chagneau-Derrode, Odile Goria, Jerôme Dumortier, Jean Paul Cervoni, Sébastien Dharancy, Nathalie Ganne-Carrié, Christophe Bureau, Nicolas Carbonell, Armand Abergel, Jean Baptiste Nousbaum, Rodolphe Anty, Hélène Barraud, Marie Pierre Ripault, Victor De Ledinghen, Anne Minello, Frédéric Oberti, Sylvie Radenne, Noelle Bendersky, Olivier Farges, Isabelle Archambeaud, Anne Guillygomarc’h, Marie Ecochard, Violaine Ozenne, Marie Noelle Hilleret, Eric Nguyen-Khac, Barbara Dauvois, Jean Marc Perarnau, Pascale Lefilliatre, Jean Jacques Raabe, Michel Doffoel, Jean Philippe Becquart, Eric Saillard, Dominique Valla, Thong Dao, and Aurélie Plessier. The epidemiology of budd-chiari syndrome in france. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 50 9:931-937, Sep 2018. URL: https://doi.org/10.1016/j.dld.2018.04.004, doi:10.1016/j.dld.2018.04.004. This article has 63 citations.

  14. (valla2009primarybuddchiarisyndrome. pages 6-7): Dominique-Charles Valla. Primary budd-chiari syndrome. Journal of hepatology, 50 1:195-203, Jan 2009. URL: https://doi.org/10.1016/j.jhep.2008.10.007, doi:10.1016/j.jhep.2008.10.007. This article has 456 citations and is from a highest quality peer-reviewed journal.

  15. (magaz2020buddchiarisyndromeanticoagulation pages 1-2): Marta Magaz, Guillem Soy, and Juan Carlos García-Pagán. Budd-chiari syndrome: anticoagulation, tips, or transplant. Current Hepatology Reports, pages 1-6, Jun 2020. URL: https://doi.org/10.1007/s11901-020-00528-8, doi:10.1007/s11901-020-00528-8. This article has 4 citations.

  16. (martens2015buddchiarisyndrome pages 5-7): Pieter Martens and Frederik Nevens. Budd-chiari syndrome. United European Gastroenterology Journal, 3:489-500, Dec 2015. URL: https://doi.org/10.1177/2050640615582293, doi:10.1177/2050640615582293. This article has 102 citations and is from a peer-reviewed journal.

  17. (karns2024a27yearoldfemale pages 1-2): John P. Karns, An Nguyen, Nikita Wong, Aisha True-Malhotra, Dennis Smythe, and Raghavendra C Vemulapalli. A 27-year-old female with jak2 mutation: a case of budd-chiari syndrome secondary to prolonged oral contraceptive pill use. Cureus, Jul 2024. URL: https://doi.org/10.7759/cureus.64858, doi:10.7759/cureus.64858. This article has 0 citations.

  18. (porrello2023buddchiarisyndromeimaging pages 2-3): Giorgia Porrello, Giuseppe Mamone, and Roberto Miraglia. Budd-chiari syndrome imaging diagnosis: state of the art and future perspectives. Diagnostics, 13:2256, Jul 2023. URL: https://doi.org/10.3390/diagnostics13132256, doi:10.3390/diagnostics13132256. This article has 35 citations.

  19. (goel2015budd–chiarisyndromeinvestigation pages 1-2): Rishi M Goel, Emma L Johnston, Kamal V Patel, and Terence Wong. Budd–chiari syndrome: investigation, treatment and outcomes. Postgraduate Medical Journal, 91:692-697, Oct 2015. URL: https://doi.org/10.1136/postgradmedj-2015-133402, doi:10.1136/postgradmedj-2015-133402. This article has 54 citations and is from a peer-reviewed journal.

  20. (rossle2023interventionaltreatmentof pages 13-14): Martin Rössle. Interventional treatment of budd–chiari syndrome. Diagnostics, 13:1458, Apr 2023. URL: https://doi.org/10.3390/diagnostics13081458, doi:10.3390/diagnostics13081458. This article has 15 citations.

  21. (craciun2024tipswitha pages 1-2): Rares Craciun, Romeo Chira, Andrada Nemes, Horia Stefanescu, Simona Cocu, and Bogdan Procopet. Tips with a twist � the real life management of a case of budd-chiarirelated acute liver and subsequent multiple organ failure. Current Medical Imaging Formerly Current Medical Imaging Reviews, Oct 2024. URL: https://doi.org/10.2174/1573405620666230908111803, doi:10.2174/1573405620666230908111803. This article has 1 citations.

  22. (porrello2023buddchiarisyndromeimaging pages 3-5): Giorgia Porrello, Giuseppe Mamone, and Roberto Miraglia. Budd-chiari syndrome imaging diagnosis: state of the art and future perspectives. Diagnostics, 13:2256, Jul 2023. URL: https://doi.org/10.3390/diagnostics13132256, doi:10.3390/diagnostics13132256. This article has 35 citations.

  23. (shukla2021buddchiarisyndromeconsensus pages 5-6): Akash Shukla, Ananta Shreshtha, Amar Mukund, Chhagan Bihari, C. E. Eapen, Guohong Han, Hemant Deshmukh, Ian Homer Y. Cua, Cosmas Rinaldi Adithya Lesmana, Mamun Al Meshtab, Masayoshi Kage, Roongruedee Chaiteeraki, Sombat Treeprasertsuk, Suprabhat Giri, Sundeep Punamiya, Valerie Paradis, Xingshun Qi, Yasuhiko Sugawara, Zaigham Abbas, and Shiv Kumar Sarin. Budd-chiari syndrome: consensus guidance of the asian pacific association for the study of the liver (apasl). Hepatology International, 15:531-567, Jun 2021. URL: https://doi.org/10.1007/s12072-021-10189-4, doi:10.1007/s12072-021-10189-4. This article has 116 citations and is from a peer-reviewed journal.

  24. (porrello2023buddchiarisyndromeimaging pages 5-8): Giorgia Porrello, Giuseppe Mamone, and Roberto Miraglia. Budd-chiari syndrome imaging diagnosis: state of the art and future perspectives. Diagnostics, 13:2256, Jul 2023. URL: https://doi.org/10.3390/diagnostics13132256, doi:10.3390/diagnostics13132256. This article has 35 citations.

  25. (elkilany2022percutaneoustransluminalangioplasty pages 12-13): Aboelyazid Elkilany, Mohamed Alwarraky, Timm Denecke, and Dominik Geisel. Percutaneous transluminal angioplasty for symptomatic hepatic vein-type budd-chiari syndrome: feasibility and long-term outcomes. Scientific Reports, Aug 2022. URL: https://doi.org/10.1038/s41598-022-16818-8, doi:10.1038/s41598-022-16818-8. This article has 2 citations and is from a peer-reviewed journal.

  26. (rossle2023interventionaltreatmentof pages 1-2): Martin Rössle. Interventional treatment of budd–chiari syndrome. Diagnostics, 13:1458, Apr 2023. URL: https://doi.org/10.3390/diagnostics13081458, doi:10.3390/diagnostics13081458. This article has 15 citations.

  27. (gavriilidis2022stateofthe pages 3-5): Paschalis Gavriilidis, Gabriele Marangoni, Jawad Ahmad, and Daniel Azoulay. State of the art, current perspectives, and controversies of budd-chiari syndrome: a review. Journal of Clinical Medicine Research, 14:147-157, Apr 2022. URL: https://doi.org/10.14740/jocmr4724, doi:10.14740/jocmr4724. This article has 38 citations.

  28. (mukhiya2023survivalandclinical pages 1-2): Gauri Mukhiya, Dechao Jiao, Xinwei Han, Xueliang Zhou, and Gaurab Pokhrel. Survival and clinical success of endovascular intervention in patients with budd-chiari syndrome: a systematic review. Journal of Clinical Imaging Science, 13:5, Jan 2023. URL: https://doi.org/10.25259/jcis_130_2022, doi:10.25259/jcis_130_2022. This article has 9 citations.

  29. (rossle2023interventionaltreatmentof media 5657bdfb): Martin Rössle. Interventional treatment of budd–chiari syndrome. Diagnostics, 13:1458, Apr 2023. URL: https://doi.org/10.3390/diagnostics13081458, doi:10.3390/diagnostics13081458. This article has 15 citations.

  30. (monaco2023directoralanticoagulants pages 13-14): Giovanni Monaco, Luca Bucherini, Bernardo Stefanini, Fabio Piscaglia, Francesco Giuseppe Foschi, and Luca Ielasi. Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: a state of art. World Journal of Gastroenterology, 29:4962-4974, Sep 2023. URL: https://doi.org/10.3748/wjg.v29.i33.4962, doi:10.3748/wjg.v29.i33.4962. This article has 16 citations.

  31. (magaz2020buddchiarisyndromeanticoagulation pages 4-5): Marta Magaz, Guillem Soy, and Juan Carlos García-Pagán. Budd-chiari syndrome: anticoagulation, tips, or transplant. Current Hepatology Reports, pages 1-6, Jun 2020. URL: https://doi.org/10.1007/s11901-020-00528-8, doi:10.1007/s11901-020-00528-8. This article has 4 citations.

  32. (khan2019reviewarticlea pages 10-11): Faisal Khan, Matthew J. Armstrong, Homoyon Mehrzad, Frederick Chen, Desley Neil, Rachel Brown, Owen Cain, and Dhiraj Tripathi. Review article: a multidisciplinary approach to the diagnosis and management of budd‐chiari syndrome. Alimentary Pharmacology & Therapeutics, 49:840-863, Mar 2019. URL: https://doi.org/10.1111/apt.15149, doi:10.1111/apt.15149. This article has 76 citations and is from a highest quality peer-reviewed journal.

  33. (NCT06960473 chunk 1): A Prospective Study on IVUS and DSA Guidance in the Treatment of Budd-Chiari Syndrome. The Affiliated Hospital of Xuzhou Medical University. 2025. ClinicalTrials.gov Identifier: NCT06960473

  34. (NCT02201485 chunk 1): Guohong Han. Budd-Chiari Syndrome in China: Balloon Angioplasty Alone or Combined With Stent Placement?. Air Force Military Medical University, China. 2014. ClinicalTrials.gov Identifier: NCT02201485

  35. (NCT05117684 chunk 1): To Compare "Balloon Occluded Thrombolysis" With "Conventional Catheter Directed Thrombolysis" in Thrombotically Occluded DIPSS Stent in Patients of Budd- Chiari Syndrome.. Institute of Liver and Biliary Sciences, India. 2021. ClinicalTrials.gov Identifier: NCT05117684

  36. (NCT05123326 chunk 2): Madhumita Premkumar. Global Coagulation Assessment in Portal Vein Thrombosis and Budd-Chiari Syndrome. Post Graduate Institute of Medical Education and Research, Chandigarh. 2021. ClinicalTrials.gov Identifier: NCT05123326

  37. (NCT03541057 chunk 1): Thomas Reiberger. Vienna Vascular Liver Disease Study. Medical University of Vienna. 2017. ClinicalTrials.gov Identifier: NCT03541057